Lpath Back In Play

By Cris Frangold: Macular degeneration is one of the most debilitating age-related degenerative medical conditions. It results in the loss of vision leading to difficulty in reading or recognizing faces. The condition worsens with age if not treated effectively.

By Chemistfrog: What is wet AMD?

ByPropThink: By Jake King

By Brian L.

By Michael Morhamus:One of the things that makes what is happening at Lpath Inc. (LPTN.OB) so intriguing is the unique scope of the firm’s work in Lipid Signaling. If you haven’t already heard, the scientific team there has recognized the value of identification and development of new regulating mechanisms involving lipid signaling molecules and modifiers.

Jason Chew submits: Pegylated interferon plus ribavirin is the current standard of care for HCV treatment. However, it is a 48-week treatment and is only effective in about 50% of patients.

By Brian L. Wilson:One of the biggest success stories that we've seen in the history of recent drug launches was with the AMD (Age-related Macular Degeneration) treatment EYLEA (aflibercept) - the flagship product of its parent company Regeneron Pharmaceuticals (NASDAQ: REGN).

By Brian L. Wilson:A relatively untapped field within the pharmaceutical industry lies in lipid-based therapies, particularly with the use of monoclonal antibodies. One of the top leaders in this emerging field is Lpath Inc. (LPTN.OB), a small pharmaceutical company which had its IPO at the end of 2005. Leading the company’s research is Roger Sabbadini, a former professor of biology from the Univesity of California, San Diego.